|1.||Hayardeny, Liat: 12 articles (06/2015 - 10/2010)|
|2.||Gold, Ralf: 5 articles (06/2015 - 03/2011)|
|3.||Brück, Wolfgang: 5 articles (06/2014 - 10/2010)|
|4.||Comi, Giancarlo: 4 articles (08/2014 - 01/2012)|
|5.||Zamvil, Scott S: 3 articles (12/2014 - 01/2012)|
|6.||Thöne, Jan: 3 articles (12/2013 - 03/2011)|
|7.||D'Haens, Geert: 2 articles (08/2015 - 06/2015)|
|8.||Gurevich, M: 2 articles (06/2015 - 04/2010)|
|9.||Achiron, A: 2 articles (06/2015 - 04/2010)|
|10.||Linker, Ralf A: 2 articles (06/2015 - 01/2012)|
03/22/2005 - "Oral laquinimod in a dosage of 0.3 mg daily was well tolerated and effective in suppressing development of active lesions in relapsing multiple sclerosis."
06/01/2015 - "Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study."
08/01/2014 - "Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage."
04/01/2014 - "A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis."
10/15/2012 - "Laquinimod is an orally active molecule that showed efficacy in clinical trials in multiple sclerosis. "
|2.||Relapsing-Remitting Multiple Sclerosis
10/15/2013 - "Laquinimod is a novel orally active agent with immunomodulatory properties that was shown to be effective in suppressing disease activity in relapsing-remitting multiple sclerosis patients. "
04/15/2010 - "Laquinimod (LAQ) is a new immunomodulatory drug shown to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS); however, its molecular target pathways are not well recognized. "
05/01/2012 - "In conclusion, preclinical studies show that laquinimod's unique mechanisms of action, including its immunomodulatory and CNS-protective effects, translate into clinical benefits in relapsing-remitting multiple sclerosis patients."
03/15/2012 - "In this phase 3 study, oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis. "
03/15/2012 - "Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing-remitting multiple sclerosis. "
|3.||Demyelinating Diseases (Demyelinating Disease)
12/01/2014 - "Further, data also indicate that laquinimod acts directly on resident cells within the CNS to reduce demyelination and axonal damage. "
06/01/2014 - "Remarkably, when laquinimod treatment was initiated well into the disease course, the progressive demyelination, and axonal loss was halted. "
07/01/2013 - "Our data suggest a novel neuroprotective mechanism by which laquinimod might in vivo protect from neuronal damage occurring as a consequence of inflammatory immune-mediated demyelination."
10/15/2012 - "Furthermore, CNS injury, manifested by astrogliosis, demyelination and axonal damages, was significantly reduced following laquinimod treatment, indicating its immunomodulatory and neuroprotective activity."
10/08/2010 - "We investigated the effect of laquinimod on inflammatory demyelination, axonal damage, cytokine profiles and migratory capacities of lymphocytes in C57BL/6 mice with active EAE induced with MOG(35-55) peptide. "
|4.||Autoimmune Diseases (Autoimmune Disease)
04/01/2002 - "These effects indicate that ABR-215062 may mediate its effects by regulation of Th1/Th2 cytokine balance and suggest that ABR-215062 is potentially a new chemical entity for effective treatment of autoimmune diseases."
03/01/2011 - "Laquinimod is a new quinolone-carboxamide that has shown efficacy in various animal models of autoimmune disease, including MS. Laquinimod shows immunomodulatory effects, probably through Th1/Th2 shift, but does not lead to immunosuppression. "
11/01/2004 - "Laquinimod therefore represents a new orally active immunoregulatory drug without general immunosuppressive properties with a potential for the treatment of severe autoimmune diseases like MS."
07/01/2009 - "To review current experience with laquinimod as a novel immunomodulatory therapy for MS. Laquinimod is a new quinolonecarboxamide that has demonstrated efficacy in animal models of several autoimmune diseases, including MS. It shows immunomodulatory effects, likely through Th1/Th2 shift, but does not lead to immunosuppression. "
|5.||Crohn Disease (Crohn's Disease)
08/01/2015 - "A phase II study of laquinimod in Crohn's disease."
06/01/2015 - "Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients. "
12/01/2015 - "The aim of the study was to investigate the therapeutic effect of laquinimod on spontaneous colitis in interleukin-10-gene-deficient mice, an animal model of Crohn's disease. "
12/01/2015 - "Our results indicated that laquinimod treatment ameliorates colitis in Il10(-/-) mice and improves intestinal barrier function, which may support a new therapeutic approach to Crohn's disease."
08/01/2015 - "Laquinimod is an oral therapeutic agent under investigation for the treatment of Crohn's disease (CD), Huntington's disease, lupus nephritis and multiple sclerosis. "
|6.||Intravenous Immunoglobulins (IVIG)
|8.||Interleukin-10 (Interleukin 10)